Results 21 to 30 of about 6,369 (156)

Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization

South Asian Journal of Cancer, 2021
Methods This is a retrospective study. G-CSF was administered in the dose of 10 μg/kg subcutaneous as a single dose for 4 days. On day 5, peripheral blood stem cell (PBSC) apheresis was performed using Haemonetics MCS plus or COBE Spectra apheresis ...
Sadik Husian, Preethi Jeyaraman, S. K. Gupta, Reeta Rai, Sangeeta Pathak, Nitin Dayal, Rahul Naithani   +6 more
doaj   +1 more source

Prediction of Survival Benefit of Filgrastim in Adult and Pediatric Patients With Acute Radiation Syndrome

Clinical and Translational Science, 2020
Acute exposure to high doses of radiation leads to severe myelosuppression, but few treatments are currently available to treat hematopoietic syndrome of acute radiation syndrome.
John Harrold, Per Olsson Gisleskog, Juan Jose Perez‐Ruixo, Isabelle Delor, Andrew Chow, Philippe Jacqmin, Murad Melhem   +6 more
doaj   +1 more source

Filgrastim-induced cutaneous vasculitis in a patient undergoing stem cell mobilization

Iraqi Journal of Hematology
Neupogen (filgrastim), a granulocyte colony-stimulating factor, is widely utilized for the management of chemotherapy-induced neutropenia and as part of mobilization regimens for hematopoietic stem cell transplantation.
Ghada H. Alani
doaj   +1 more source

Usefulness of pegfilgrastim for allogeneic peripheral blood stem cell collection from healthy donors

Transfusion, EarlyView.
Abstract Background Granulocyte colony‐stimulating factor (G‐CSF)‐based mobilization is essential for peripheral blood stem cell (PBSC) collection for allogeneic transplantation. Conventional daily G‐CSF requires repeated dosing and dose adjustment and often necessitates leukapheresis over multiple consecutive days, increasing donor burden. Single‐dose
Tomoshige Shimizu, Tomoyasu Jo, Noriyoshi Yoshinaga, Takashi Sakamoto, Hiroyuki Matsui, Toshio Kitawaki, Junya Kanda, Momoko Nishikori, Kouhei Yamashita, Miki Nagao, Akifumi Takaori‐Kondo, Yasuyuki Arai   +11 more
wiley   +1 more source

Tolerability and efficacy of chemosaturation in combination with systemic therapy for metastatic uveal melanoma

International Journal of Cancer, Volume 159, Issue 2, Page 339-344, 15 July 2026.
What's new? Uveal melanoma is the most common primary intraocular cancer in adults, and up to half of patients develop metastatic disease, predominantly in the liver, where prognosis remains poor despite promising treatment options. In this study, the authors evaluated the safety and efficacy of administering systemic therapy within 40 days of liver ...
Patrick Kasteleiner, Gerd Grözinger, Jörg Schmehl, Lukas Flatz, Andrea Forschner   +4 more
wiley   +1 more source

Embryonal Paratesticular Rhabdomyosarcoma Masquerading as an Inguinal Hernia: A Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Embryonal paratesticular rhabdomyosarcoma can mimic benign inguinoscrotal conditions such as inguinal hernia. In children with persistent, painless scrotal masses, early cross‐sectional imaging and prompt radical inguinal orchiectomy with histopathological confirmation are essential.
Somaya Al Kiswani, Qusai Otoum, Morad Abbas, Momen Sawafta, Abdallateef salih, Omar Jaber, Azza Gharaibeh, Abdullah Nofal   +7 more
wiley   +1 more source

Primary Extramedullary Acute Promyelocytic Leukemia Presenting as Cauda Equina Syndrome: A Rare Case Report and Diagnostic Challenge

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT APL presenting as an extramedullary mass is exceedingly rare. Here, we describe extramedullary APL causing cauda equina syndrome, underscoring the diagnostic challenges associated with an atypical presentation, highlighting the complexity of distinguishing extramedullary APL from other conditions, and discussing the stepwise approach to ...
Amir Ali, Marc Ringor, Arbab Khalid, Diana Garcia, Ravishankar Konchada, Ramalingam Ratnasabapathy, Yuna Chae, Arman Melikyan, George Yaghmour   +8 more
wiley   +1 more source

Methotrexate Toxicity in a Patient With Renal Failure Despite a Normal Methotrexate Concentration: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Methotrexate (MTX) is a folate antagonist widely used as a disease‐modifying antirheumatic drug (DMARD) in rheumatoid arthritis (RA), as well as in several malignancies and autoimmune disorders. Although low‐dose MTX (5–20 mg/week) is generally considered safe, it has a narrow therapeutic index, and toxicity can occur even at therapeutic doses,
Fatemeh Afra, Mahshad Ghoddusi, Mahsa Mottahedi, Maryam Albaji, Samira Kafan, Roya Saedpanah, Amir Shokri, Elham Nazar   +7 more
wiley   +1 more source

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

ClinicoEconomics and Outcomes Research, 2018
Lee S Schwartzberg,1,2 Lincy S Lal,3 Sanjeev Balu,4 Kim Campbell,4 Lee Brekke,3 Caitlin Elliott,3 Stephanie Korrer3 1West Cancer Center, Memphis, TN, USA; 2Division of Hematology and Oncology, University of Tennessee, Memphis, TN, USA; 3Health Economics ...
Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, Elliott C, Korrer S   +6 more
doaj  

A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. [PDF]

PLoS ONE, 2013
PurposeTo assess the non-inferiority of pegfilgrastim versus filgrastim in speeding the recovery of polymorphonuclear cells (PMN) in pediatric patients who underwent autologous peripheral blood stem cell transplant (PBSCT).MethodsThe sample size of this ...
Simone Cesaro, Francesca Nesi, Gloria Tridello, Massimo Abate, Irene Sara Panizzolo, Rita Balter, Elisabetta Calore   +6 more
doaj   +1 more source